Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Integration of drug safety monitoring in tuberculosis treatment programmes: country experiences.

Tiemersma E, van den Hof S, Dravniece G, Wares F, Molla Y, Permata Y, Lukitosari E, Quelapio M, Aung ST, Aung KM, Thuy HT, Hoa VD, Sulaimanova M, Sagyndikova S, Makhmudova M, Soliev A, Kimerling M.

Eur Respir Rev. 2019 Oct 11;28(153). pii: 180115. doi: 10.1183/16000617.0115-2018. Print 2019 Sep 30. Review.

2.

Evidence-informed policy making at country level: lessons learned from the South African Tuberculosis Think Tank.

White RG, Charalambous S, Cardenas V, Hippner P, Sumner T, Bozzani F, Mudzengi D, Houben RMGJ, Collier D, Kimerling ME, Vassall A, Pillay Y, Churchyard G.

Int J Tuberc Lung Dis. 2018 Jun 1;22(6):606-613. doi: 10.5588/ijtld.17.0485.

3.

Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study.

Zignol M, Cabibbe AM, Dean AS, Glaziou P, Alikhanova N, Ama C, Andres S, Barbova A, Borbe-Reyes A, Chin DP, Cirillo DM, Colvin C, Dadu A, Dreyer A, Driesen M, Gilpin C, Hasan R, Hasan Z, Hoffner S, Hussain A, Ismail N, Kamal SMM, Khanzada FM, Kimerling M, Kohl TA, Mansjö M, Miotto P, Mukadi YD, Mvusi L, Niemann S, Omar SV, Rigouts L, Schito M, Sela I, Seyfaddinova M, Skenders G, Skrahina A, Tahseen S, Wells WA, Zhurilo A, Weyer K, Floyd K, Raviglione MC.

Lancet Infect Dis. 2018 Jun;18(6):675-683. doi: 10.1016/S1473-3099(18)30073-2. Epub 2018 Mar 21. Erratum in: Lancet Infect Dis. 2018 Mar 27;:.

4.

Defining the research agenda to measure and reduce tuberculosis stigmas.

Macintyre K, Bakker MI, Bergson S, Bhavaraju R, Bond V, Chikovore J, Colvin C, Craig GM, Cremers AL, Daftary A, Engel N, France NF, Jaramillo E, Kimerling M, Kipp A, Krishnaratne S, Mergenthaler C, Ngicho M, Redwood L, Rood EJJ, Sommerland N, Stangl A, van Rie A, van Brakel W, Wouters E, Zwerling A, Mitchell EMH.

Int J Tuberc Lung Dis. 2017 Nov 1;21(11):87-96. doi: 10.5588/ijtld.17.0151.

5.

Modelling the social and structural determinants of tuberculosis: opportunities and challenges.

Pedrazzoli D, Boccia D, Dodd PJ, Lönnroth K, Dowdy DW, Siroka A, Kimerling ME, White RG, Houben RMGJ.

Int J Tuberc Lung Dis. 2017 Sep 1;21(9):957-964. doi: 10.5588/ijtld.16.0906. Review.

6.

Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models.

Menzies NA, Gomez GB, Bozzani F, Chatterjee S, Foster N, Baena IG, Laurence YV, Qiang S, Siroka A, Sweeney S, Verguet S, Arinaminpathy N, Azman AS, Bendavid E, Chang ST, Cohen T, Denholm JT, Dowdy DW, Eckhoff PA, Goldhaber-Fiebert JD, Handel A, Huynh GH, Lalli M, Lin HH, Mandal S, McBryde ES, Pandey S, Salomon JA, Suen SC, Sumner T, Trauer JM, Wagner BG, Whalen CC, Wu CY, Boccia D, Chadha VK, Charalambous S, Chin DP, Churchyard G, Daniels C, Dewan P, Ditiu L, Eaton JW, Grant AD, Hippner P, Hosseini M, Mametja D, Pretorius C, Pillay Y, Rade K, Sahu S, Wang L, Houben RMGJ, Kimerling ME, White RG, Vassall A.

Lancet Glob Health. 2016 Nov;4(11):e816-e826. doi: 10.1016/S2214-109X(16)30265-0. Epub 2016 Oct 6.

7.

Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models.

Houben RMGJ, Menzies NA, Sumner T, Huynh GH, Arinaminpathy N, Goldhaber-Fiebert JD, Lin HH, Wu CY, Mandal S, Pandey S, Suen SC, Bendavid E, Azman AS, Dowdy DW, Bacaër N, Rhines AS, Feldman MW, Handel A, Whalen CC, Chang ST, Wagner BG, Eckhoff PA, Trauer JM, Denholm JT, McBryde ES, Cohen T, Salomon JA, Pretorius C, Lalli M, Eaton JW, Boccia D, Hosseini M, Gomez GB, Sahu S, Daniels C, Ditiu L, Chin DP, Wang L, Chadha VK, Rade K, Dewan P, Hippner P, Charalambous S, Grant AD, Churchyard G, Pillay Y, Mametja LD, Kimerling ME, Vassall A, White RG.

Lancet Glob Health. 2016 Nov;4(11):e806-e815. doi: 10.1016/S2214-109X(16)30199-1. Epub 2016 Oct 6.

8.

Tuberculosis screening yield of asylum seekers in Europe.

de Vries G, van Rest J, Meijer W, Schimmel H, Wolters B, van Hest R, Kimerling M.

Eur Respir J. 2016 Oct;48(4):1255-1256. doi: 10.1183/13993003.01617-2016. No abstract available.

9.

Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project.

Zignol M, Dean AS, Alikhanova N, Andres S, Cabibbe AM, Cirillo DM, Dadu A, Dreyer A, Driesen M, Gilpin C, Hasan R, Hasan Z, Hoffner S, Husain A, Hussain A, Ismail N, Kamal M, Mansjö M, Mvusi L, Niemann S, Omar SV, Qadeer E, Rigouts L, Ruesch-Gerdes S, Schito M, Seyfaddinova M, Skrahina A, Tahseen S, Wells WA, Mukadi YD, Kimerling M, Floyd K, Weyer K, Raviglione MC.

Lancet Infect Dis. 2016 Oct;16(10):1185-1192. doi: 10.1016/S1473-3099(16)30190-6. Epub 2016 Jul 7.

10.

Preventing and controlling tuberculosis among refugees in Europe: more needed for high-risk populations.

de Vries G, van Rest J, Meijer W, Wolters B, van Hest R, Kimerling M.

Eur Respir J. 2016 Jul;48(1):274-6. doi: 10.1183/13993003.00575-2016. No abstract available.

11.

TIME Impact - a new user-friendly tuberculosis (TB) model to inform TB policy decisions.

Houben RM, Lalli M, Sumner T, Hamilton M, Pedrazzoli D, Bonsu F, Hippner P, Pillay Y, Kimerling M, Ahmedov S, Pretorius C, White RG.

BMC Med. 2016 Mar 24;14:56. doi: 10.1186/s12916-016-0608-4.

12.

Defining the needs for next generation assays for tuberculosis.

Denkinger CM, Kik SV, Cirillo DM, Casenghi M, Shinnick T, Weyer K, Gilpin C, Boehme CC, Schito M, Kimerling M, Pai M.

J Infect Dis. 2015 Apr 1;211 Suppl 2:S29-38. doi: 10.1093/infdis/jiu821. Review.

13.

How can mathematical models advance tuberculosis control in high HIV prevalence settings?

Houben RM, Dowdy DW, Vassall A, Cohen T, Nicol MP, Granich RM, Shea JE, Eckhoff P, Dye C, Kimerling ME, White RG; TB MAC TB-HIV meeting participants.

Int J Tuberc Lung Dis. 2014 May;18(5):509-14. doi: 10.5588/ijtld.13.0773. Review.

14.

The utility of stool cultures for diagnosing tuberculosis in people living with the human immunodeficiency virus.

Oramasionwu GE, Heilig CM, Udomsantisuk N, Kimerling ME, Eng B, Nguyen HD, Thai S, Keo C, McCarthy KD, Varma JK, Cain KP.

Int J Tuberc Lung Dis. 2013 Aug;17(8):1023-8. doi: 10.5588/ijtld.13.0061.

15.

Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action.

Wells WA, Boehme CC, Cobelens FG, Daniels C, Dowdy D, Gardiner E, Gheuens J, Kim P, Kimerling ME, Kreiswirth B, Lienhardt C, Mdluli K, Pai M, Perkins MD, Peter T, Zignol M, Zumla A, Schito M.

Lancet Infect Dis. 2013 May;13(5):449-58. doi: 10.1016/S1473-3099(13)70025-2. Epub 2013 Mar 24. Review.

16.

Use of anti-retroviral therapy in tuberculosis patients on second-line anti-TB regimens: a systematic review.

Arentz M, Pavlinac P, Kimerling ME, Horne DJ, Falzon D, Schünemann HJ, Royce S, Dheda K, Walson JL; ART study group.

PLoS One. 2012;7(11):e47370. doi: 10.1371/journal.pone.0047370. Epub 2012 Nov 5. Review.

17.

Clinical research and development of tuberculosis diagnostics: moving from silos to synergy.

Nahid P, Kim PS, Evans CA, Alland D, Barer M, Diefenbach J, Ellner J, Hafner R, Hamilton CD, Iademarco MF, Ireton G, Kimerling ME, Lienhardt C, MacKenzie WR, Murray M, Perkins MD, Posey JE, Roberts T, Sizemore C, Stevens WS, Via L, Williams SD, Yew WW, Swindells S.

J Infect Dis. 2012 May 15;205 Suppl 2:S159-68. doi: 10.1093/infdis/jis194. Epub 2012 Apr 3. Review.

18.

Which new diagnostics for tuberculosis, and when?

Cobelens F, van den Hof S, Pai M, Squire SB, Ramsay A, Kimerling ME; Evidence for Scale-up Group.

J Infect Dis. 2012 May 15;205 Suppl 2:S191-8. doi: 10.1093/infdis/jis188. Epub 2012 Apr 3.

PMID:
22476716
19.

Nontuberculous mycobacterial disease in patients with HIV in Southeast Asia.

McCarthy KD, Cain KP, Winthrop KL, Udomsantisuk N, Lan NT, Sar B, Kimerling ME, Kanara N, Lynen L, Monkongdee P, Tasaneeyapan T, Varma JK.

Am J Respir Crit Care Med. 2012 May 1;185(9):981-8. doi: 10.1164/rccm.201107-1327OC. Epub 2012 Feb 16.

PMID:
22345581
20.

Size and usage patterns of private TB drug markets in the high burden countries.

Wells WA, Ge CF, Patel N, Oh T, Gardiner E, Kimerling ME.

PLoS One. 2011 May 4;6(5):e18964. doi: 10.1371/journal.pone.0018964.

21.

Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies.

Getahun H, Kittikraisak W, Heilig CM, Corbett EL, Ayles H, Cain KP, Grant AD, Churchyard GJ, Kimerling M, Shah S, Lawn SD, Wood R, Maartens G, Granich R, Date AA, Varma JK.

PLoS Med. 2011 Jan 18;8(1):e1000391. doi: 10.1371/journal.pmed.1000391.

22.

Bloodstream infections among HIV-infected outpatients, Southeast Asia.

Varma JK, McCarthy KD, Tasaneeyapan T, Monkongdee P, Kimerling ME, Buntheoun E, Sculier D, Keo C, Phanuphak P, Teeratakulpisarn N, Udomsantisuk N, Dung NH, Lan NT, Yen NT, Cain KP.

Emerg Infect Dis. 2010 Oct;16(10):1569-75. doi: 10.3201/eid1610.091686.

23.

Extensive drug resistance in malaria and tuberculosis.

Wongsrichanalai C, Varma JK, Juliano JJ, Kimerling ME, MacArthur JR.

Emerg Infect Dis. 2010 Jul;16(7):1063-7. doi: 10.3201/eid1607.091840.

24.

The incremental cost-effectiveness of engaging private practitioners to refer tuberculosis suspects to DOTS services in Jogjakarta, Indonesia.

Mahendradhata Y, Probandari A, Ahmad RA, Utarini A, Trisnantoro L, Lindholm L, van der Werf MJ, Kimerling M, Boelaert M, Johns B, Van der Stuyft P.

Am J Trop Med Hyg. 2010 Jun;82(6):1131-9. doi: 10.4269/ajtmh.2010.09-0447.

25.

An algorithm for tuberculosis screening and diagnosis in people with HIV.

Cain KP, McCarthy KD, Heilig CM, Monkongdee P, Tasaneeyapan T, Kanara N, Kimerling ME, Chheng P, Thai S, Sar B, Phanuphak P, Teeratakulpisarn N, Phanuphak N, Nguyen HD, Hoang TQ, Le HT, Varma JK.

N Engl J Med. 2010 Feb 25;362(8):707-16. doi: 10.1056/NEJMoa0907488.

26.

Outcomes after chemotherapy with WHO category II regimen in a population with high prevalence of drug resistant tuberculosis.

Matthys F, Rigouts L, Sizaire V, Vezhnina N, Lecoq M, Golubeva V, Portaels F, Van der Stuyft P, Kimerling M.

PLoS One. 2009 Nov 23;4(11):e7954. doi: 10.1371/journal.pone.0007954.

27.

The cost of intensified case finding and isoniazid preventive therapy for HIV-infected patients in Battambang, Cambodia.

Sutton BS, Arias MS, Chheng P, Eang MT, Kimerling ME.

Int J Tuberc Lung Dis. 2009 Jun;13(6):713-8.

PMID:
19460246
28.

Tuberculosis co-morbidity and perceptions about health care among HIV-infected plasma donors in rural China.

Qian HZ, Li Q, Yao H, Ruan Y, Kristensen S, Schumacher JE, Pan SW, Shao Y, Kimerling ME.

Southeast Asian J Trop Med Public Health. 2009 Jan;40(1):108-12.

PMID:
19323042
29.

Predictors of smear-negative pulmonary tuberculosis in HIV-infected patients, Battambang, Cambodia.

Tamhane A, Chheng P, Dobbs T, Mak S, Sar B, Kimerling ME.

Int J Tuberc Lung Dis. 2009 Mar;13(3):347-54.

PMID:
19275795
30.

Scaling up programmatic management of drug-resistant tuberculosis: a prioritized research agenda.

Cobelens FG, Heldal E, Kimerling ME, Mitnick CD, Podewils LJ, Ramachandran R, Rieder HL, Weyer K, Zignol M; Working Group on MDR-TB of the Stop TB Partnership.

PLoS Med. 2008 Jul 8;5(7):e150. doi: 10.1371/journal.pmed.0050150. No abstract available.

31.

Voluntary counselling and testing uptake and HIV prevalence among tuberculosis patients in Jogjakarta, Indonesia.

Mahendradhata Y, Ahmad RA, Kusuma TA, Boelaert M, Van der Werf MJ, Kimerling ME, Van der Stuyft P.

Trans R Soc Trop Med Hyg. 2008 Oct;102(10):1003-10. doi: 10.1016/j.trstmh.2008.04.042. Epub 2008 Jun 20.

PMID:
18571213
32.

Early lessons from the integration of tuberculosis and HIV services in primary care centers in Lusaka, Zambia.

Harris JB, Hatwiinda SM, Randels KM, Chi BH, Kancheya NG, Jham MA, Samungole KV, Tambatamba BC, Cantrell RA, Levy JW, Kimerling ME, Reid SE.

Int J Tuberc Lung Dis. 2008 Jul;12(7):773-9.

PMID:
18544203
33.

Pulmonary tuberculosis among patients visiting a voluntary confidential counseling and testing center, Cambodia.

Chheng P, Tamhane A, Natpratan C, Tan V, Lay V, Sar B, Kimerling ME.

Int J Tuberc Lung Dis. 2008 Mar;12(3 Suppl 1):54-62.

PMID:
18302824
34.

Clinical evaluation of the microscopic observation drug susceptibility assay for detection of Mycobacterium tuberculosis resistance to isoniazid or rifampin.

Mello FC, Arias MS, Rosales S, Marsico AG, Pavón A, Alvarado-Gálvez C, Pessôa CL, Pérez M, Andrade MK, Kritski AL, Fonseca LS, Chaisson RE, Kimerling ME, Dorman SE.

J Clin Microbiol. 2007 Oct;45(10):3387-9. Epub 2007 Aug 15.

35.

Clinical evaluation of the microscopic-observation drug-susceptibility assay for detection of tuberculosis.

Arias M, Mello FC, Pavón A, Marsico AG, Alvarado-Gálvez C, Rosales S, Pessôa CL, Pérez M, Andrade MK, Kritski AL, Fonseca LS, Chaisson RE, Kimerling ME, Dorman SE.

Clin Infect Dis. 2007 Mar 1;44(5):674-80. Epub 2007 Jan 22.

PMID:
17278058
36.

Hospital DOTS linkage in Indonesia: a model for DOTS expansion into government and private hospitals.

Irawati SR, Basri C, Arias MS, Prihatini S, Rintiswati N, Voskens J, Kimerling ME.

Int J Tuberc Lung Dis. 2007 Jan;11(1):33-9.

PMID:
17217127
37.

Evaluating the strengths and weaknesses of tuberculosis educational activities for prisoners in Honduras.

Mangan JM, Arias MS, Sierra T, Perez M, Medina RL, Yanez R, Kimerling ME.

Int J Tuberc Lung Dis. 2006 Oct;10(10):1152-8.

PMID:
17044210
38.

Time for tuberculosis contact tracing in correctional facilities?

Lobato MN, Kimerling ME, Taylor Z.

Int J Tuberc Lung Dis. 2005 Nov;9(11):1179. No abstract available.

PMID:
16333921
39.

The need for longitudinal screening studies in prison TB control.

Kimerling ME, Kluge H.

Int J Tuberc Lung Dis. 2005 Jun;9(6):589. No abstract available.

PMID:
15971382
40.

Long-term molecular analysis of tuberculosis strains in alabama, a state characterized by a largely indigenous, low-risk population.

Kempf MC, Dunlap NE, Lok KH, Benjamin WH Jr, Keenan NB, Kimerling ME.

J Clin Microbiol. 2005 Feb;43(2):870-8.

41.

Standardizing contact investigation protocols.

Gerald LB, Bruce F, Brooks CM, Brook N, Kimerling ME, Windsor RA, Bailey WC.

Int J Tuberc Lung Dis. 2003 Dec;7(12 Suppl 3):S369-74.

42.

The risk of MDR-TB and polyresistant tuberculosis among the civilian population of Tomsk city, Siberia, 1999.

Kimerling ME, Slavuckij A, Chavers S, Peremtin GG, Tonkel T, Sirotkina O, Golubchikova V, Baddeley A.

Int J Tuberc Lung Dis. 2003 Sep;7(9):866-72.

PMID:
12971671
43.

Prevalence of pulmonary tuberculosis among HIV-infected persons in a home care program in Phnom Penh, Cambodia.

Kimerling ME, Schuchter J, Chanthol E, Kunthy T, Stuer F, Glaziou P, Ee O.

Int J Tuberc Lung Dis. 2002 Nov;6(11):988-94.

PMID:
12475145
44.

Molecular differentiation of Mycobacterium tuberculosis strains without IS6110 insertions.

Lok KH, Benjamin WH Jr, Kimerling ME, Pruitt V, Lathan M, Razeq J, Hooper N, Cronin W, Dunlap NE.

Emerg Infect Dis. 2002 Nov;8(11):1310-3.

45.

Molecular typing of Mycobacterium tuberculosis strains with a common two-band IS6110 pattern.

Lok KH, Benjamin WH Jr, Kimerling ME, Pruitt V, Mulcahy D, Robinson N, Keenan NB, Dunlap NE.

Emerg Infect Dis. 2002 Nov;8(11):1303-5.

46.

A decision tree for tuberculosis contact investigation.

Gerald LB, Tang S, Bruce F, Redden D, Kimerling ME, Brook N, Dunlap N, Bailey WC.

Am J Respir Crit Care Med. 2002 Oct 15;166(8):1122-7.

PMID:
12379558
47.
48.

Predictive model to identify positive tuberculosis skin test results during contact investigations.

Bailey WC, Gerald LB, Kimerling ME, Redden D, Brook N, Bruce F, Tang S, Duncan S, Brooks CM, Dunlap NE.

JAMA. 2002 Feb 27;287(8):996-1002.

PMID:
11866647
49.

Identification of a contaminating Mycobacterium tuberculosis strain with a transposition of an IS6110 insertion element resulting in an altered spoligotype.

Benjamin WH Jr, Lok KH, Harris R, Brook N, Bond L, Mulcahy D, Robinson N, Pruitt V, Kirkpatrick DP, Kimerling ME, Dunlap NE.

J Clin Microbiol. 2001 Mar;39(3):1092-6.

50.

The Russian equation: an evolving paradigm in tuberculosis control.

Kimerling ME.

Int J Tuberc Lung Dis. 2000 Dec;4(12 Suppl 2):S160-7. No abstract available.

PMID:
11144547

Supplemental Content

Loading ...
Support Center